West Pharmaceutical Services Announces Leadership Changes

Ticker: WST · Form: 8-K · Filed: Apr 14, 2025 · CIK: 105770

Sentiment: neutral

Topics: leadership-change, executive-appointment, board-composition

TL;DR

West Pharma's CFO is changing, new director appointed, and a board member resigned.

AI Summary

On April 9, 2025, West Pharmaceutical Services, Inc. reported a departure of a director, Mr. David L. Johnson, who resigned from the Board of Directors. The company also announced the election of Ms. R. Sarah Keohane as a new director and the appointment of Mr. Kevin J. Cannon as Chief Financial Officer, effective April 15, 2025. Additionally, the company disclosed compensatory arrangements for certain officers.

Why It Matters

Changes in key leadership positions like CFO and board composition can signal shifts in company strategy or financial oversight, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Leadership changes, especially the CFO role, can introduce uncertainty and potential strategic shifts, warranting closer monitoring by investors.

Key Players & Entities

FAQ

Who has resigned from the Board of Directors?

Mr. David L. Johnson has resigned from the Board of Directors.

Who has been elected as a new director?

Ms. R. Sarah Keohane has been elected as a new director.

Who has been appointed as the new Chief Financial Officer?

Mr. Kevin J. Cannon has been appointed as the new Chief Financial Officer.

When is the appointment of the new CFO effective?

The appointment of Mr. Kevin J. Cannon as Chief Financial Officer is effective April 15, 2025.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is April 9, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 14, 2025 by David L. Johnson regarding WEST PHARMACEUTICAL SERVICES INC (WST).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing